科塞特不动产

Cencora's 15min chart: RSI Overbought, KDJ Death Cross detected.

Morgan Stanley upgrades Cencora to Overweight, raises PT to $400 from $361.

Cencora

Cardinal Health

McKesson

Morgan Stanley Upgrades Cencora, Calls Drug Distributors' Industry a 'Golden Era'

Cencora Q1 Earnings Preview: Specialty and International Momentum Expected to Boost Results

Cencora's 15min chart shows Bollinger Bands Narrowing and KDJ Death Cross.

Catalyst<ul> <li>Most analysts rate COR Buy or Strong Buy, showing broad institutional optimism.</li> <li>Small and Extra-large fund flow buckets show positive inflow trends indicating potential demand.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant with 3 bearish signals versus 1 bullish signal in recent technical analysis.</li> <li>Revenue-MV and operating cash flow metrics are deteriorating, which may affect future growth prospects.</li></ul>

Key Factors

Cencora is positioning itself as a central node in a consolidating pharmaceutical distribution sector by building resilient, scalable supply chains to meet growing demand for complex drug portfolios.

Recent Updates

COR News